BACKGROUND: Individuals with type 1 diabetes may have low IGF-1, related to insulinopenia and insulin resistance. There are few longitudinal studies of IGF-1 levels to establish its pattern in type 1 diabetes with duration and age, and to examine whether IGF-1 tracks within individuals over time. We examine age and duration trends, and the relationship of IGF-1 to gender, glycaemic control, insulin level and other factors. METHODS: Participants in the Wisconsin Diabetes Registry Study, an incident cohort study of type 1 diabetes diagnosed May 1987-April 1992, were followed for up to 18 years with IGF-1 samples up to age 45 for women and age 37 for men. RESULTS: IGF-1 is lower with type 1 diabetes than in normative samples. Although, the pattern across age resembles that in normative samples with a peak in adolescence and slow decline after age 20, the adolescent peak is delayed for women with type 1 diabetes. There was low to moderate tracking of IGF-1 within an individual. Higher insulin dose was associated with higher IGF-1 as was puberty, and female gender. Adjusted for these factors, IGF-1 declined rapidly across early diabetes duration. Lower HbA1c was most strongly related to higher IGF-1 at Tanner stages 1 and 2. CONCLUSIONS: IGF-1 is low in type 1 diabetes, with a delayed adolescent peak in women and is especially influenced by glycaemic control in early and pre-adolescence. High variability within an individual is likely a challenge in investigating associations between IGF-1 and long-term outcomes, and may explain contradictory findings.
BACKGROUND: Individuals with type 1 diabetes may have low IGF-1, related to insulinopenia and insulin resistance. There are few longitudinal studies of IGF-1 levels to establish its pattern in type 1 diabetes with duration and age, and to examine whether IGF-1 tracks within individuals over time. We examine age and duration trends, and the relationship of IGF-1 to gender, glycaemic control, insulin level and other factors. METHODS:Participants in the Wisconsin Diabetes Registry Study, an incident cohort study of type 1 diabetes diagnosed May 1987-April 1992, were followed for up to 18 years with IGF-1 samples up to age 45 for women and age 37 for men. RESULTS:IGF-1 is lower with type 1 diabetes than in normative samples. Although, the pattern across age resembles that in normative samples with a peak in adolescence and slow decline after age 20, the adolescent peak is delayed for women with type 1 diabetes. There was low to moderate tracking of IGF-1 within an individual. Higher insulin dose was associated with higher IGF-1 as was puberty, and female gender. Adjusted for these factors, IGF-1 declined rapidly across early diabetes duration. Lower HbA1c was most strongly related to higher IGF-1 at Tanner stages 1 and 2. CONCLUSIONS:IGF-1 is low in type 1 diabetes, with a delayed adolescent peak in women and is especially influenced by glycaemic control in early and pre-adolescence. High variability within an individual is likely a challenge in investigating associations between IGF-1 and long-term outcomes, and may explain contradictory findings.
Authors: Rakesh Amin; Carl Schultz; Ken Ong; Jan Frystyk; R Neil Dalton; Les Perry; Hans Ørskov; David B Dunger Journal: Diabetes Care Date: 2003-05 Impact factor: 19.112
Authors: Georg Brabant; Alexander von zur Mühlen; Christian Wüster; Michael B Ranke; Jürgen Kratzsch; Wieland Kiess; Jean-Marie Ketelslegers; Lars Wilhelmsen; Lena Hulthén; Bernhard Saller; Anders Mattsson; Jürgen Wilde; Rudolf Schemer; Peter Kann Journal: Horm Res Date: 2003
Authors: Shoshana Yakar; Jennifer Setser; Hong Zhao; Bethel Stannard; Martin Haluzik; Vaida Glatt; Mary L Bouxsein; John J Kopchick; Derek LeRoith Journal: J Clin Invest Date: 2004-01 Impact factor: 14.808
Authors: Michael Bernd Ranke; Karl Josef Osterziel; Roland Schweizer; Burkhardt Schuett; Karin Weber; Patricia Röbbel; Arnold Vornwald; Gunnar Blumenstock; Martin W Elmlinger Journal: Clin Chem Lab Med Date: 2003-10 Impact factor: 3.694
Authors: Melanie R Shapiro; Clive H Wasserfall; Sean M McGrail; Amanda L Posgai; Rhonda Bacher; Andrew Muir; Michael J Haller; Desmond A Schatz; Johnna D Wesley; Matthias von Herrath; William A Hagopian; Cate Speake; Mark A Atkinson; Todd M Brusko Journal: Diabetes Date: 2019-12-11 Impact factor: 9.461
Authors: Mohamad-Reza Aghanoori; Darrell R Smith; Shiva Shariati-Ievari; Andrew Ajisebutu; Annee Nguyen; Fiona Desmond; Carlos H A Jesus; Xiajun Zhou; Nigel A Calcutt; Michel Aliani; Paul Fernyhough Journal: Mol Metab Date: 2018-11-28 Impact factor: 7.422
Authors: Masao Kakoki; Purushotham V Ramanathan; John R Hagaman; Ruriko Grant; Jennifer C Wilder; Joan M Taylor; J Charles Jennette; Oliver Smithies; Nobuyo Maeda-Smithies Journal: Commun Biol Date: 2021-06-23